All News
FDA Action Alert for February 7
Specialty vaccine company Valneva and Pfizer have reported positive Phase II data from their clinical trial evaluating a Lyme Disease vaccine candidate.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
Gaithersburg, Maryland-based Arcellx, Inc. unveiled its ticker symbol on the Nasdaq Friday, hitting the market at a cool $15 per share.
After 50 years, Sanofi is giving itself a bit of a branding make-over with a new logo and a restructuring of its corporate umbrella supporting its three-year-old “Play to Win” strategy.
StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.
Novartis reported its full-year financials this week for 2021, and overall, the news was good. Of concern, however, is the company’s Sandoz generics unit.
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
This particular renewal panel discussion took an unexpected turn, focusing on Biogen’s controversial drug.
UCB hit the mark in its Phase III clinical trial assessing zilucoplan, while Vanda failed its late-stage study of tradipitant.
Preclinical models indicate that pairing specific cancer treatments with precision nutritional interventions increased treatment efficacy by as much as 500%.
Data from Phase III ECHELON-1 clinical study conducted with either stage III or stage IV cHL showed consistent improvement in OS across each of the six 28-day cycles completed.
The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.
The collaboration will focus on expanding targeted protein degradation therapies through the discovery of previously unrecognized molecular glues or monovalent degraders.
CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.
In Roche’s 2021 annual report, the company detailed that group sales rose 9%, pharmaceutical sales up 3%, and diagnostics up a whopping 29%.
Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.
Research Roundup for February 4